Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Pfizer Inc (PFE) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 195,036,944
  • Shares Outstanding, K 6,065,650
  • Annual Sales, $ 48,851 M
  • Annual Income, $ 6,960 M
  • 36-Month Beta 0.91
  • Price/Sales 3.91
  • Price/Book 3.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.83 +6.03%
on 11/03/16
33.83 -6.50%
on 11/10/16
+1.00 (+3.26%)
since 11/02/16
3-Month
29.83 +6.03%
on 11/03/16
34.99 -9.60%
on 09/06/16
-3.14 (-9.03%)
since 09/02/16
52-Week
28.25 +11.96%
on 02/08/16
37.39 -15.41%
on 08/01/16
-1.27 (-3.86%)
since 12/02/15

Most Recent Stories

More News
New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Today, Pfizer Inc. (NYSE:PFE) announced new data from a randomized Phase 2 study of glasdegib (PF-04449913), an oral, smoothened (SMO) inhibitor, showing the addition of glasdegib to low-dose...

Spark Therapeutics and Pfizer Present Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting

Together, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days

Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma

Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.

Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug

Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from...

Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda

This week, companies like Merck (MRK) and Pfizer (PFE) provided updates on their pipelines.

5 Top Performing S&P 500 Stocks of November

President-elect Donald Trump has proposed a raft of fiscal-stimulus measures, which has pushed the S&P 500 to almost an all-time high in November

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Citi 2016 Global...

Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study

Pfizer, Inc. (PFE) recently announced that its experimental biosimilar of Roche Holding AG's (RHHBY) breast cancer drug - Herceptin - has reached the primary endpoint in a pivotal study.

IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery

IBM (NYSE: IBM) Watson Health and Pfizer Inc. (NYSE: PFE) today announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer's research in immuno-oncology, an approach...

ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.

ARIAD Pharmaceuticals, Inc. (ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on accelerated...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Support & Resistance

2nd Resistance Point 31.94
1st Resistance Point 31.79
Last Price 31.63
1st Support Level 31.42
2nd Support Level 31.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.